![](https://bloximages.newyork1.vip.townnews.com/wfmz.com/content/tncms/custom/image/b9818ac0-ee9a-11e9-8e9f-a3b831b71481.jpg?resize=600%2C338)
CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline
SUZHOU, China, Feb. 9, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that its key …